Solid Biosciences announced a widely anticipated update on their INSPIRE DUCHENNE Phase 1/2 clinical trial of SGT-003

Solid Biosciences announced a widely anticipated update on their INSPIRE DUCHENNE Phase 1/2 clinical trial of SGT-003

Solid Biosciences announced a widely anticipated update on their INSPIRE DUCHENNE Phase 1/2 clinical trial of SGT-003, their investigational micro-dystrophin gene therapy for Duchenne muscular dystrophy.15 participants have received SGT-003 so far across sites in the U.S., Canada, Italy, and the UK. No serious treatment-related adverse effects have been reported, and early safety results remain positive. The company plans to dose a minimum of 20…